ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
